Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL

British Journal of Clinical Pharmacology

Volumn 53, Issue 6, 2002, Pages 576-581

  Martin Facklam, Meret ^a   Burhenne, Jürgen ^a   Ding, Reinhard ^a   Fricker, Ruth ^a   Mikus, Gerd ^a   Walter Sack, Ingeborg ^a   Haefeli, Walter E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bioavailability; Cremophor EL; P glycoprotein; Saquinavir

Indexed keywords

CREMOPHOR; GLYCOPROTEIN P; SAQUINAVIR; DRUG DERIVATIVE; DRUG VEHICLE; GLYCEROL; PROTEINASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BIOAVAILABILITY; BLOOD; DRUG ANTAGONISM; ORAL DRUG ADMINISTRATION; VEHICLES;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GLYCEROL; HIV PROTEASE INHIBITORS; HUMAN; MALE; P-GLYCOPROTEIN; SAQUINAVIR; SUPPORT, NON-U.S. GOV'T; VEHICLES; HUMANS;

EID: 0035987163     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01595.x     Document Type: Article

References (22)

1. Biochemical, cellular, and pharmacological aspects of the multidrug transporter
2. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man
3. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
4. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man
5. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection
6. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
7. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
8. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
9. Role of P-glycoprotein and cytochrome P450, 3A in limiting oral absorption of peptides and peptidomimetics
10. Increased drug delivery to the brain by P-glycoprotein inhibition
11. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs
12. Effect of polyoxyl 35 castor oil and polysorbate 80 on the intestinal absorption of digoxin in vitro
13. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice
14. Determination of saquinavir in human plasma by LC/MS/MS
15. Analytical methods validation. Bioavailability, bioequivalence and pharmacokinetic studies. Conference report
16. Rapid Detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridization probes
17. Pharmacokinetics of the HIV-proteinase inhibitor, Ro 31-8959, after single and multiple oral doses in healthy volunteers
18. Theoretical and experimental studies of transport of micelle-solubilized solutes
19. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells
20. 'Inactive' ingedients may alter bioavailability of drugs through effects on p-glycoprotein (PGP) and CYP3A